NASDAQ:IKNA

Ikena Oncology Competitors

$14.46
-0.07 (-0.48 %)
(As of 06/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.38
$14.99
50-Day Range
$13.27
$25.64
52-Week Range
$13.00
$37.61
Volume113,277 shs
Average Volume198,039 shs
Market Capitalization$518.41 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Ikena Oncology (NASDAQ:IKNA) Vs. KYMR, TBIO, CRTX, REPL, SGMO, and ALEC

Should you be buying IKNA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Ikena Oncology, including Kymera Therapeutics (KYMR), Translate Bio (TBIO), Cortexyme (CRTX), Replimune Group (REPL), Sangamo Therapeutics (SGMO), and Alector (ALEC).

Ikena Oncology (NASDAQ:IKNA) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Kymera Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ikena Oncology00303.00
Kymera Therapeutics02602.75

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Kymera Therapeutics has a consensus target price of $56.00, suggesting a potential upside of 25.73%. Given Ikena Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Kymera Therapeutics.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 50.6% of Kymera Therapeutics shares are owned by institutional investors. 23.3% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ikena OncologyN/AN/AN/A
Kymera TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Ikena Oncology and Kymera Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena OncologyN/AN/AN/AN/AN/A
Kymera Therapeutics$34.03 million58.94$-45,590,000.00($3.15)-14.14

Ikena Oncology has higher earnings, but lower revenue than Kymera Therapeutics.

Ikena Oncology (NASDAQ:IKNA) and Translate Bio (NASDAQ:TBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Translate Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ikena Oncology00303.00
Translate Bio04702.64

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Translate Bio has a consensus target price of $25.80, suggesting a potential upside of 14.72%. Given Ikena Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Translate Bio.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 88.7% of Translate Bio shares are owned by institutional investors. 9.4% of Translate Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Translate Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ikena OncologyN/AN/AN/A
Translate Bio-7.69%-13.81%-6.07%

Valuation & Earnings

This table compares Ikena Oncology and Translate Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena OncologyN/AN/AN/AN/AN/A
Translate Bio$138.81 million12.19$-53,790,000.00($0.80)-28.11

Ikena Oncology has higher earnings, but lower revenue than Translate Bio.

Summary

Ikena Oncology beats Translate Bio on 5 of the 9 factors compared between the two stocks.

Ikena Oncology (NASDAQ:IKNA) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Cortexyme, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ikena Oncology00303.00
Cortexyme21302.17

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Cortexyme has a consensus target price of $43.3333, suggesting a potential downside of 24.12%. Given Ikena Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Cortexyme.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 62.6% of Cortexyme shares are owned by institutional investors. 20.2% of Cortexyme shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Cortexyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ikena OncologyN/AN/AN/A
CortexymeN/A-45.84%-42.02%

Valuation & Earnings

This table compares Ikena Oncology and Cortexyme's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena OncologyN/AN/AN/AN/AN/A
CortexymeN/AN/A$-76,850,000.00($2.63)-21.71

Summary

Ikena Oncology beats Cortexyme on 4 of the 6 factors compared between the two stocks.

Ikena Oncology (NASDAQ:IKNA) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Replimune Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ikena Oncology00303.00
Replimune Group00803.00

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Replimune Group has a consensus target price of $56.00, suggesting a potential upside of 55.38%. Given Ikena Oncology's higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Replimune Group.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 73.6% of Replimune Group shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Replimune Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ikena OncologyN/AN/AN/A
Replimune GroupN/A-20.81%-18.53%

Valuation & Earnings

This table compares Ikena Oncology and Replimune Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena OncologyN/AN/AN/AN/AN/A
Replimune GroupN/AN/A$-80,870,000.00($1.75)-20.59

Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Ikena Oncology and Sangamo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ikena Oncology00303.00
Sangamo Therapeutics01502.83

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Sangamo Therapeutics has a consensus target price of $22.40, suggesting a potential upside of 92.77%. Given Ikena Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe Ikena Oncology is more favorable than Sangamo Therapeutics.

Insider & Institutional Ownership

55.9% of Ikena Oncology shares are owned by institutional investors. Comparatively, 55.3% of Sangamo Therapeutics shares are owned by institutional investors. 2.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Sangamo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ikena OncologyN/AN/AN/A
Sangamo Therapeutics-94.38%-24.82%-13.50%

Valuation & Earnings

This table compares Ikena Oncology and Sangamo Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena OncologyN/AN/AN/AN/AN/A
Sangamo Therapeutics$118.19 million14.15$-121,000,000.00($0.90)-12.91

Ikena Oncology has higher earnings, but lower revenue than Sangamo Therapeutics.

Summary

Ikena Oncology beats Sangamo Therapeutics on 6 of the 9 factors compared between the two stocks.

Ikena Oncology (NASDAQ:IKNA) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Ikena Oncology and Alector, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ikena Oncology00303.00
Alector00403.00

Ikena Oncology currently has a consensus target price of $30.00, suggesting a potential upside of 107.47%. Alector has a consensus target price of $34.40, suggesting a potential upside of 64.91%. Given Ikena Oncology's higher possible upside, research analysts plainly believe Ikena Oncology is more favorable than Alector.

Insider and Institutional Ownership

55.9% of Ikena Oncology shares are held by institutional investors. Comparatively, 57.6% of Alector shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Ikena Oncology and Alector's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ikena OncologyN/AN/AN/A
Alector-1,122.03%-69.73%-39.83%

Valuation and Earnings

This table compares Ikena Oncology and Alector's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ikena OncologyN/AN/AN/AN/AN/A
Alector$21.10 million78.86$-190,230,000.00($2.45)-8.51

Ikena Oncology has higher earnings, but lower revenue than Alector.


Ikena Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$44.54-0.1%$2.01 billion$34.03 million-14.14
Translate Bio logo
TBIO
Translate Bio
1.2$22.49-8.1%$1.69 billion$138.81 million-97.78Analyst Revision
News Coverage
Cortexyme logo
CRTX
Cortexyme
1.2$57.11-1.8%$1.69 billionN/A-20.40
Replimune Group logo
REPL
Replimune Group
1.7$36.04-2.2%$1.68 billionN/A-20.59
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.4$11.62-1.5%$1.67 billion$118.19 million-13.20
Alector logo
ALEC
Alector
1.3$20.86-2.1%$1.66 billion$21.10 million-8.12Insider Selling
REGENXBIO logo
RGNX
REGENXBIO
1.7$38.52-1.0%$1.64 billion$154.57 million-12.35News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.6$37.76-1.5%$1.63 billion$33.19 million-6.48Analyst Report
Immunocore logo
IMCR
Immunocore
1.2$36.50-2.7%$1.57 billion$38.67 million-10.20
IBRX
ImmunityBio
2.2$14.03-2.6%$1.53 billion$110,000.00-19.76Upcoming Earnings
Ocugen logo
OCGN
Ocugen
1.2$7.56-2.0%$1.50 billion$42.62 million-24.39
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$66.13-1.0%$1.47 billionN/A-31.05News Coverage
AlloVir logo
ALVR
AlloVir
1.7$21.02-2.5%$1.37 billion$170,000.00-8.12
BioAtla logo
BCAB
BioAtla
2.0$39.23-1.8%$1.32 billion$430,000.000.00Insider Selling
News Coverage
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.7$15.50-0.7%$1.30 billionN/A-4.01
VALN
Valneva
2.1$25.99-0.4%$1.30 billionN/A0.00
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.7$25.96-3.2%$1.23 billion$100.56 million-3.88
Agenus logo
AGEN
Agenus
1.4$5.38-3.7%$1.20 billion$88.17 million-5.22
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.3$14.64-2.9%$1.11 billion$475.82 million-12.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.8$25.38-1.7%$1.10 billionN/A-4.63
Vaxcyte logo
PCVX
Vaxcyte
1.6$21.48-0.7%$1.10 billionN/A-7.28
Mesoblast logo
MESO
Mesoblast
1.4$8.39-2.4%$1.09 billion$32.16 million-8.83
Immunovant logo
IMVT
Immunovant
1.8$11.00-0.8%$1.08 billionN/A-8.87
Inhibrx logo
INBX
Inhibrx
1.6$26.75-6.3%$1.01 billion$12.89 million-8.89High Trading Volume
Scholar Rock logo
SRRK
Scholar Rock
1.5$28.76-4.2%$989.78 million$15.40 million-9.62
Vaxart logo
VXRT
Vaxart
1.3$7.85-0.5%$959.80 million$4.05 million-16.70
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.7$25.07-0.8%$956.52 millionN/A-2.31News Coverage
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
2.2$25.14-0.8%$953.23 millionN/A-7.39
Sutro Biopharma logo
STRO
Sutro Biopharma
1.5$18.57-0.7%$856.32 million$42.72 million-24.76Analyst Report
News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.49-1.3%$820.16 million$83.14 million-4.58
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.8$23.19-1.8%$814.06 millionN/A-8.05
Passage Bio logo
PASG
Passage Bio
2.0$13.76-1.5%$742.72 millionN/A-4.85News Coverage
Curis logo
CRIS
Curis
1.7$7.60-1.1%$695.67 million$10.84 million-15.20
MeiraGTx logo
MGTX
MeiraGTx
1.6$15.59-1.0%$690.36 million$15.56 million-9.45
Cellectis logo
CLLS
Cellectis
1.4$14.80-1.3%$672.82 million$82.46 million-5.48
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$17.45-1.2%$665.93 millionN/A-7.39
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.4$4.16-7.2%$646.76 million$3.96 million-4.38News Coverage
TALS
Talaris Therapeutics
2.0$15.37-0.5%$634.94 millionN/A0.00
DBV Technologies logo
DBVT
DBV Technologies
1.3$5.76-0.3%$632.87 million$11.28 million-4.57
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.6$30.32-6.0%$622.29 millionN/A-7.02Analyst Report
Precision BioSciences logo
DTIL
Precision BioSciences
1.4$10.70-0.6%$615.04 million$24.28 million-5.63Insider Selling
News Coverage
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.5$4.82-3.3%$596.57 million$2.60 million-3.62Gap Up
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.7$9.02-1.0%$560.64 millionN/A-2.19
Compugen logo
CGEN
Compugen
1.4$7.78-1.4%$532.31 million$2 million-19.95
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.1$19.09-0.5%$495.92 millionN/A-6.63News Coverage
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.7$15.08-2.2%$490.46 million$17.44 million-4.38
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.5$6.83-2.2%$481.62 million$1.72 million-2.54
Gritstone bio logo
GRTS
Gritstone bio
1.5$9.76-4.8%$480.17 million$4.04 million-4.95News Coverage
Gap Up
ACHL
Achilles Therapeutics
1.9$11.42-1.3%$463.90 millionN/A0.00
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$12.32-0.7%$445.52 millionN/A-5.18
This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.